Pipobroman

Summary

Pipobroman (CHEMBL1585) is an approved small-molecule antineoplastic agent (ATC L01AX02); indicated across 2 conditions including neoplasm and acquired polycythemia vera.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01AX02
• Indications: 2 conditions
• Chemistry: 356.05 Da · C10H16Br2N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1585
Name	Pipobroman
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4842
ChEBI	CHEBI:8242
ATC	L01AX02
Molecular formula	C10H16Br2N2O2
Molecular weight	356.05
InChIKey	NJBFOOCLYDNZJN-UHFFFAOYSA-N

SMILES: C1CN(CCN1C(=O)CCBr)C(=O)CCBr

IUPAC name: 3-bromo-1-[4-(3-bromopropanoyl)piperazin-1-yl]propan-1-one

ChEBI definition: An N-acylpiperazine that is piperazine in which each of the nitrogens has been acylated by a 3-bromopropionoyl group. An anti-cancer drug.

Pharmacological roles (ChEBI): antineoplastic agent, alkylating agent.

Also known as: A-8103, NSC-25154, Pipobroman, Vercyte, SID26748793, PIPOBROMAN, SID86412, SID144204955, SID170465158

Patent coverage: 11,126 distinct patent families (49,628 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 10 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Lysine-specific demethylase 4E, Ubiquitin carboxyl-terminal hydrolase 2, Prelamin-A/C, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Menin/Histone-lysine N-methyltransferase MLL, Cytochrome P450 3A4, Cruzipain, Aldehyde dehydrogenase 1A1, 3-hydroxyacyl-CoA dehydrogenase type-2.

Bioactivity

ChEMBL activities: 8 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP3A4	7.2	Potency	63.1	nM	CHEMBL_ACT_4961368
CYP3A4	7.2	Potency	63.1	nM	CHEMBL_ACT_5026857
LMNA	6.3	Potency	501.2	nM	CHEMBL_ACT_3652109
ALDH1A1	6.05	Potency	891.3	nM	CHEMBL_ACT_4150142
P25779	5.2	Potency	6310	nM	CHEMBL_ACT_3980475
TDP1	5.1	Potency	7943	nM	CHEMBL_ACT_3928215
MEN1	5	Potency	10000	nM	CHEMBL_ACT_4557022
USP2	5	Potency	10000	nM	CHEMBL_ACT_4711598

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
acquired polycythemia vera	3	MONDO:0009891	EFO:0002429

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).